COMMUNIQUÉS West-GlobeNewswire

Eccogene Receives U.S. FDA Clearance to Initiate Phase 2a MOSAIC Trial of ECC4703 and ECC0509 for MASH
06/10/2025
BOSTON and SHANGHAI, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Eccogene, a clinical-stage biopharmaceutical company developing next-generation oral small molecule therapeutics for chronic cardiometabolic and inflammatory [...]
Maze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of Directors
06/10/2025
Mr. Hoppenot, a seasoned biotech leader who has driven transformative therapies to market, joins Maze to fuel its evolution into a leading clinical-stage biotech SOUTH SAN FRANCISCO, Calif., Oct. 06, 2025 (GLOBE [...]
Invivyd Announces U.S. IND Clearance and Alignment with U.S. FDA on Pivotal Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
06/10/2025
The DECLARATION (safety and efficacy vs. placebo) and LIBERTY (exploratory safety head-to-head and combination with mRNA-based COVID vaccination) clinical trials are expected to begin around year-end 2025; top-line data [...]
Kraig Biocraft Laboratories Announces Production Expansion
06/10/2025
ANN ARBOR, Mich., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a world leader in spider silk technology*, today announced that it is preparing to add a [...]
iMDx Reports Kidney Transplant Patient Achieved ‘Immune Reset’ with Novel Therapy and GraftAssure Monitoring
06/10/2025
American Journal of Transplantation study positions GraftAssure as potentially essential in managing immunosuppression treatment in kidney transplant patients with certain cancers GraftAssure used to help avoid [...]
Onco360® Has Been Selected as a Specialty Pharmacy Partner for INLURIYO™ (imlunestrant)
06/10/2025
LOUISVILLE, Ky., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Onco360 ® , the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Eli Lilly for Inluriyo™ (imlunestrant), indicated for the [...]
Context Therapeutics Announces Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
06/10/2025
PHILADELPHIA, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies [...]
Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program
06/10/2025
Marker Therapeutics initiated Phase 1 RAPID study to investigate Multi-Antigen Recognizing (MAR) T cells as an Off-the-Shelf (OTS) product to accelerate time to treatment OTS product was well tolerated - safety data [...]
Theriva™ Biologics Announces Presentation Describing Next Generation Oncolytic Adenovirus VCN-12 at the 32nd Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)
06/10/2025
- Preclinical data for VCN-12, the next candidate from Theriva’s VCN-X discovery program, highlight a novel mechanism of action with the potential to significantly improve antitumor effects - - Pre-ESGCT meeting [...]
PBC Biomed Appoints Mark McMahan as Chief Commercial Officer
06/10/2025
SHANNON, Ireland, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Irish medical device company PBC Biomed today announced the appointment of Mark McMahan as Chief Commercial Officer, effective October 2025. McMahan, formerly Vice [...]
Trogenix announces £70 million / $95 million Series A financing to drive clinical development of potentially curative therapies for aggressive cancers
06/10/2025
Trogenix's breakthrough Odysseus® platform targets cancer cells to deliver precision therapies with curative “one and done” potential across multiple aggressive, treatment-resistant cancers Financing round led by IQ [...]
Harness Therapeutics Announces Launch of MISBA® Duo Platform and Research Collaboration with Ono Venture Investment
06/10/2025
Harness Therapeutics Announces Launch of MISBA® Duo Platform and Research Collaboration with Ono Venture Investment Proprietary MISBA Duo technology is the first platform to enable simultaneous, controlled upregulation [...]
Onco3R Therapeutics Announces Completion of First Cohort in Phase 1 Trial of Novel SIK3 inhibitor O3R-5671 and Oral Presentation at UEGW 2025
06/10/2025
Dosing of first cohort in Phase 1 trial of O3R-5671 complete with no adverse findings On track for full data read out in the first half of 2026 Discovery and preclinical data on O3R-5671 selected for oral presentation [...]
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies
06/10/2025
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies 50 mg dose of once-daily obefazimod achieved [...]
Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-class Neuroprotective Therapy
06/10/2025
ZUG, Switzerland, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Successful meeting with FDA enables advancement into pivotal development with Privosegtor in Acute Optic Neuritis (AON) and Non-arteritic Anterior Ischemic Optic [...]
Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-class Neuroprotective Therapy
06/10/2025
Successful meeting with FDA enables advancement into pivotal development with Privosegtor in Acute Optic Neuritis (AON) and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) Oculis will launch the PIONEER Program [...]
European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency
06/10/2025
LONDON, UK and REYKJAVIK, ICELAND (OCTOBER 6, 2025) — Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease [...]
European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency
06/10/2025
LONDON and REYKJAVIK, Iceland, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare [...]
Fagron receives Brazilian antitrust clearance for Purifarma and Injeplast acquisitions
06/10/2025
Regulated information - inside information Nazareth (Belgium)/Rotterdam (The Netherlands), 6 October 2025 – 7:00 AM CET Fagron receives Brazilian antitrust clearance for Purifarma and Injeplast acquisitions Fagron, the [...]

Pages